ADYNOVATE Drug Profile

Summary for Tradename: ADYNOVATE

High Confidence Patents:	32
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ADYNOVATE

Recent Clinical Trials for ADYNOVATE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Chulalongkorn University	Phase 4
Jessica Garcia	Phase 4
Federico II University	Phase 4

See all ADYNOVATE clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ADYNOVATE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ADYNOVATE Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	10,022,437	2035-08-28	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	10,065,991	2035-05-06	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	10,213,492	2032-09-03	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADYNOVATE	antihemophilic factor (recombinant), pegylated	For Injection	125566	10,259,837	2036-02-25	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ADYNOVATE Derived from Patent Text Search

No patents found based on company disclosures

International Patents for ADYNOVATE

Country	Patent Number	Estimated Expiration
China	104327182
Japan	2025066162
New Zealand	555032
San Marino	T202000241

Supplementary Protection Certificates for ADYNOVATE

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
691	Finland
1990029-9	Sweden		PRODUCT NAME: DAMOCTOCOG ALFA PEGOL; REG. NO/DATE: EU/1/18/1324 20181126
PA2019509,C1824988	Lithuania		PRODUCT NAME: DAMOKTOKOGAS ALFA PEGOLAS; REGISTRATION NO/DATE: EU/1/18/1324 20181122
2290031-0	Sweden		PRODUCT NAME: RURIOCTOCOG ALFA PEGOL; REG. NO/DATE: EU/1/17/1247 20180110

Market Dynamics and Financial Trajectory for ADYNOVATE

Last updated: April 17, 2026

What is ADYNOVATE?

ADYNOVATE (antihemophilic factor [recombinant], PEGylated-aucl) is a recombinant von Willebrand factor-free, PEGylated factor VIII developed by Takeda Pharmaceuticals. Approved by the FDA in 2015, it is designed for the prophylactic and on-demand treatment of hemophilia A.

Current Market Position

ADYNOVATE is among the leading extended-half-life (EHL) factor VIII products with a globally competitive profile, aimed at reducing infusion frequency compared to conventional factor VIII therapies.

• Peak sales (2022): Estimated around $200 million globally.
• Market share (2022): Approximate 15% in the U.S. hemophilia A market.
• Pricing: Standard list prices for EHL factors ranged from $250,000 to over $350,000 annually per patient.

Market Drivers

Hemophilia A Patient Population Expansion

• Global prevalence: Approximately 1 in 5,000 male births.
• Diagnosed patients: Around 90% globally diagnosed.
• Treatment penetration: Limited in emerging markets; improved access expected to expand the market.

Demand for Extended-Half-Life Products

• Advantages: Reduced infusion frequency improves compliance and quality of life.
• Market adoption: EHL products account for 65% of the U.S. hemophilia A market (2022), up from 50% two years prior.

Competition Landscape

• Key competitors:

  • Hemlibra (emicizumab) by Roche (non-factor therapy, prophylactic use).
  • Eloctate (efmoroctocog alfa) by Takeda.
  • BAY 94-9027 (damoctocog alfa pegol) by Bayer.

• Market share battles: Hemlibra, as a bispecific antibody, has gained significant share, but factor VIII products like ADYNOVATE retain importance for on-demand and resistance cases.

Financial Trajectory

Revenue Projections (2023–2027)

Year	Estimated Revenue	Growth Rate	Key Factors
2023	$210 million	+5%	Market stabilization, competition, expanded access
2024	$230 million	+9.5%	Increased adoption, price adjustments
2025	$255 million	+11%	Launch of next-generation PEGylated products, broader access
2026	$280 million	+10%	Market saturation, increased cards from emerging markets
2027	$305 million	+9%	Competition effects, potential label expansions

Cost and Pricing Trends

• List price: Maintains premium pricing but faces pressures from biosimilars and market competition.
• Pricing strategy: Focuses on value, reliability, and expanded indications.

R&D and Pipeline

Takeda invests approximately 15% of sales into R&D, aiming to develop next-generation longer-acting products, gene therapy partnerships, and biosimilar entrants to mitigate generic competition.

Regulatory and Policy Impact

• Pricing: HTA evaluations, especially in European markets, influence pricing. High-cost therapies face pushback, leading to value-based agreements.
• Reimbursement: Coverage varies; improved HEOR data facilitates broader access.
• Label expansions: Applications for adolescent and pediatric populations could extend revenue streams.

Market Risks

• Competition from non-factor therapies: Hemlibra and others challenge traditional factor VIII therapies.
• Market saturation: Growth depends on new patient diagnoses and improved access.
• Pricing pressures: Increasing scrutiny on high-cost biologics could impact margins.

Strategic Outlook

Takeda's focus on pipeline innovation, including gene therapies and next-generation products, positions ADYNOVATE to retain relevance. Expanding access in emerging markets and real-world evidence generation remain critical.

Key Takeaways

• ADYNOVATE holds a substantial share within the hemophilia A biologics segment, with steady revenue growth expected through 2027.
• Market expansion depends heavily on penetration in emerging markets and broader indication approvals.
• Competition from non-factor therapies introduces significant uncertainty.
• Pricing pressures and biosimilar entry are potential disruptors, necessitating ongoing innovation and value demonstration.
• R&D investments, particularly in gene therapy, represent strategic steps to diversify Takeda's portfolio.

FAQs

Q1: What differentiates ADYNOVATE from other factor VIII products?
It has an extended half-life due to PEGylation, reducing infusion frequency and improving patient compliance.

Q2: How does ADYNOVATE compare in pricing to biosimilar competitors?
Premium pricing persists for ADYNOVATE, but biosimilars enter the market at lower prices, exerting downward pressure.

Q3: What is Takeda’s plan for ADYNOVATE in the next five years?
Focus on expanding indications, improving access globally, and integrating pipeline breakthroughs such as gene therapies.

Q4: How might non-factor therapies affect ADYNOVATE’s market share?
They could significantly reduce demand for factor VIII products, especially for prophylactic treatment, depending on efficacy, safety, and cost.

Q5: What are the regulatory hurdles for next-generation factor VIII therapies?
Demonstrating bioequivalence, long-term safety, and efficacy, especially for personalized and gene therapies, challenges approval pathways.

---

Sources

[1] Takeda Pharmaceuticals. (2022). ADYNOVATE Prescribing Information. Retrieved from https://www.adynovate.com
[2] IQVIA. (2022). Hemophilia Market Data.
[3] GlobalData. (2022). Hemophilia A biologics analysis.
[4] FDA. (2015). FDA approves Takeda’s ADYNOVATE for hemophilia A.
[5] EvaluatePharma. (2022). Hemophilia biologics market forecast.